A novel selective sphingosine kinase 2 inhibitor, HWG-35D, ameliorates the severity of imiquimod-induced psoriasis model by blocking Th17 differentiation of naïve CD4 T lymphocytes

Shin, Sun-Hye and Kim, Hee-Yeon and Yoon, Hee-Soo and Park, Woo-Jae and Adams, David R and Pyne, Nigel J. and Pyne, Susan and Park, Joo-Won (2020) A novel selective sphingosine kinase 2 inhibitor, HWG-35D, ameliorates the severity of imiquimod-induced psoriasis model by blocking Th17 differentiation of naïve CD4 T lymphocytes. International Journal of Molecular Sciences, 21 (21). 8371. ISSN 1422-0067

[thumbnail of Shin-etal-IJMS-2020-A-novel-selective-sphingosine-kinase-2-inhibitor-HWG-35D-ameliorates-the-severity-of-imiquimod-induced-psoriasis]
Preview
Text (Shin-etal-IJMS-2020-A-novel-selective-sphingosine-kinase-2-inhibitor-HWG-35D-ameliorates-the-severity-of-imiquimod-induced-psoriasis)
Shin_etal_IJMS_2020_A_novel_selective_sphingosine_kinase_2_inhibitor_HWG_35D_ameliorates_the_severity_of_imiquimod_induced_psoriasis.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (2MB)| Preview

    Abstract

    Sphingosine kinases (SK) catalyze the phosphorylation of sphingosine to generate sphingosine-1-phosphate. Two isoforms of SK (SK1 and SK2) exist in mammals. Previously, we showed the beneficial effects of SK2 inhibition, using ABC294640, in a psoriasis mouse model. However, ABC294640 also induces the degradation of SK1 and dihydroceramide desaturase 1 (DES1). Considering these additional effects of ABC294640, we re-examined the efficacy of SK2 inhibition in an IMQ-induced psoriasis mouse model using a novel SK2 inhibitor, HWG-35D, which exhibits nM potency and 100-fold selectivity for SK2 over SK1. Topical application of HWG-35D ameliorated IMQ-induced skin lesions and normalized the serum interleukin-17A levels elevated by IMQ. Application of HWG-35D also decreased skin mRNA levels of interleukin-17A, K6 and K16 genes induced by IMQ. Consistent with the previous data using ABC294640, HWG-35D also blocked T helper type 17 differentiation of naive CD4+ T cells with concomitant reduction of SOCS1. Importantly, HWG-35D did not affect SK1 or DES1 expression levels. These results reaffirm an important role of SK2 in the T helper type 17 response and suggest that highly selective and potent SK2 inhibitors such as HWG-35D might be of therapeutic use for the treatment of psoriasis.

    ORCID iDs

    Shin, Sun-Hye, Kim, Hee-Yeon, Yoon, Hee-Soo, Park, Woo-Jae, Adams, David R, Pyne, Nigel J. ORCID logoORCID: https://orcid.org/0000-0002-5657-4578, Pyne, Susan ORCID logoORCID: https://orcid.org/0000-0002-6608-9584 and Park, Joo-Won;